Morana Vojnic

Rutgers, The State University of New Jersey

Also affiliated with Robert Wood Johnson University Hospital, Johnson University, Environmental and Occupational Health Sciences Institute, Rutgers Cancer Institute, Robert Wood Johnson Foundation

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors”.

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Communications Biology(2020)10.1038/s42003-020-01508-w

N/A

2.2DataRank · unranked

63 citations

Nicolle E. Hofmann, Bryan D. Smith, Igor Odintsov, Morana Vojnic, Irina Linkov +10 more

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2278

N/A

0.724DataRank · unranked

124 citations

Melissa L. Johnson, Sarah Clifford, Romel Somwar, Jennifer Kherani, Jieun Son +23 more

Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.2024

N/A

0.330DataRank · unranked

8 citations

Allan J.W. Lui, Kota Ishizawa, Isao Miyazaki, Inna Khodos, Kentaro Wakayama +11 more

Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling

Disease Models & Mechanisms(2021)10.1242/dmm.047621

N/A

0DataRank · unranked

33 citations

Igor Odintsov, Zebing Liu, Allan J.W. Lui, Takuo Hayashi, Morana Vojnic +22 more

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Cancer Discovery(2022)10.1158/2159-8290.cd-21-1119

N/A

0DataRank · unranked

168 citations

Igor Odintsov, Madelyn Espinosa-Cotton, Inna Khodos, Whitney J. Sisso, Marissa S. Mattar +17 more

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

Nature Cancer(2023)10.1038/s43018-023-00630-y

N/A

0DataRank · unranked

38 citations

Igor Odintsov, Keiji Ishida, Allan J.W. Lui, Masanori Kato, Tatsuya Suzuki +28 more

Clinical and preclinical insights into a novel MDM2::PDGFRA fusion in recurrent glioblastoma

npj Precision Oncology(2025)10.1038/s41698-025-01076-4

N/A

0DataRank · unranked

2 citations

Christopher A. Febres‐Aldana, Juan Luis Gomez Marti, Saeed Asiry, Tamika Wong, John A. Boockvar +5 more

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation

Disease Models & Mechanisms(2020)10.1242/dmm.047779

N/A

0DataRank · unranked

12 citations

Igor Odintsov, Roger S. Smith, Kota Ishizawa, Allan J. W. Liu, Lukas Delasos +17 more

The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3605

N/A

0DataRank · unranked

51 citations

Allan J.W. Lui, Whitney J. Sisso, Eric Gladstone, Zebing Liu, Lukas Delasos +10 more